A deluge of weight‑loss drugs is set to transform the global fight against obesity as India prepares to unleash low‑cost generic versions of injections like Ozempic after a key patent expired

India is set to combat global obesity with affordable, generic versions of weight-loss drugs like Ozempic, following patent expirations. Read more at straitstimes.com. Read more at straitstimes.com.

Experts urge recognition of abdominal obesity as a vital sign in Asian Indians to better assess metabolic health risks.

Obesity is emerging as a key driver of India’s noncommunicable disease crisis. With nearly 1 in 4 adults overweight and abdominal obesity affecting 40%, experts warn early action is critical to curb diabetes and heart disease.

With semaglutide going off patent in India, copycat versions of Novo Nordisk’s blockbuster drugs are set to arrive at dramatically lower price points—from ₹1,290 to around ₹4,500— far below branded therapy levels,

HYDERABAD, India, Dec 24 (Reuters) - Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year. Novo's strategy emphasizes price ...

WHO Foundation and Novo Nordisk team up to combat childhood obesity in India through a scalable school-based health program.

India is grappling with a startling childhood obesity crisis, impacting 14 million youths and placing it just behind China. As wealth increases and urban life becomes the norm, unhealthy eating habits and a drop in physical activity are making matters worse.

More than 200 million school-age children between the ages of five and 19 who are overweight or living with obesity are found in just 10 countries worldwide.